Who we are ?

Theranexus is a French biotechnology company, created in 2013. We are an operational team supported by a network of highly experienced industrial and medical leaders in our target indications. We have developed a proprietary technology platform for generating IP protected New Therapeutic Entities that address unmet needs in CNS.


Our technology platform gives large opportunities for pharmaceutical companies with reduced risks and “fast to market” vehicle for:

  • The generation of New Therapeutic Entities with strong IP and premium pricing potential.
  • An innovative and unique strategy for the lifecycle management of CNS drug portfolio.
  • A potential technology for revitalizing clinical phase products where the efficacy/safety profile is hindering development.


Co-founder & Chief Executive Officer

Franck Mouthon is graduated in life sciences from Ecole Normale Supérieure (Ulm), leading French Scientific school, University Pierre & Marie Curie and Pasteur Institute. After beginning his career in French Atomic Energy Commission, he has built solid experience in research team management and project managing in CNS diseases. He obtained several competitive innovation grants and famous labels. He filed different patents linked to CNS disorders and negotiated license which led to the creation of Theranexus in 2013.


Co-founder & Chief Scientific Officer

Mathieu Charvériat is the Chief Scientific Officer of Theranexus. Mathieu holds a PhD in neurosciences from University Pierre & Marie Curie, and graduated from Ecole Polytechnique, Mines ParisTech, and Pasteur Institute. He has over 10 years of expertise in animal behavioral, neuropharmacology, preclinical drug identification, and connexin modulation.